tiprankstipranks
Trending News
More News >
MedAdvisor Limited (AU:MDR)
:MDR
Australian Market
Advertisement

MedAdvisor Limited (MDR) AI Stock Analysis

Compare
18 Followers

Top Page

AU:MDR

MedAdvisor Limited

(Sydney:MDR)

Rating:56Neutral
Price Target:
AU$0.00
▼(-100.00% Downside)
MedAdvisor Limited's overall stock score reflects strong financial performance with significant revenue growth and improved profitability. However, this is offset by weak technical indicators and a negative P/E ratio, indicating potential risks. The absence of a dividend yield and bearish trends in technical analysis also contribute to the moderate score.

MedAdvisor Limited (MDR) vs. iShares MSCI Australia ETF (EWA)

MedAdvisor Limited Business Overview & Revenue Model

Company DescriptionMedAdvisor Limited, together with its subsidiaries, develops and delivers software in Australia, the United States, the United Kingdom, and Asia. The company provides MedAdvisor, a medication and adherence platform that focuses on improving health outcomes by connecting health professionals with their patients using technology and enhancing medication adherence through health programs; THRiV, an intelligent digital adherence solution; and GuildCare, a cloud-based platform that offers healthcare solutions and medicines information for consumers, health professionals, and other partners. MedAdvisor Limited was incorporated in 2010 and is headquartered in Camberwell, Australia.
How the Company Makes MoneyMedAdvisor Limited makes money primarily through its software-as-a-service (SaaS) model, where it charges subscription fees to pharmacies and healthcare providers who use its platform to engage with patients. Additionally, the company may generate revenue through partnerships with pharmaceutical companies for targeted health campaigns and patient engagement initiatives. These partnerships can involve fees for access to MedAdvisor's user base or for specific marketing campaigns aimed at improving medication adherence. The company may also explore additional revenue streams such as data analytics services, leveraging insights gathered from its platform to offer valuable information to healthcare stakeholders.

MedAdvisor Limited Financial Statement Overview

Summary
MedAdvisor Limited has demonstrated significant financial improvements with strong revenue growth, improved profitability, and a robust cash flow position. The company has effectively managed its costs and maintained a solid balance sheet with low leverage.
Income Statement
78
Positive
MedAdvisor Limited has shown significant improvement in its financial performance. The revenue growth rate from 2023 to 2024 was 24.6%, indicating strong top-line growth. The gross profit margin improved to 19.4%, and the net profit margin turned positive at 0.65%, reflecting enhanced profitability. The EBIT and EBITDA margins also improved substantially, demonstrating effective cost management and operational efficiency.
Balance Sheet
72
Positive
The company maintains a stable balance sheet with a debt-to-equity ratio of 0.24, indicating low financial leverage and reduced risk. The equity ratio is 52.2%, showing a solid financial structure. Return on equity improved to 1.54%, but remains modest, suggesting room for enhanced shareholder value creation.
Cash Flow
75
Positive
MedAdvisor's cash flow position has strengthened, with a free cash flow growth rate of 305.4% from 2023 to 2024. The operating cash flow to net income ratio is 6.55, indicating efficient cash generation relative to profit. The free cash flow to net income ratio of 4.23 further supports the company's strong cash conversion capability.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue122.11M97.96M67.75M38.77M9.60M
Gross Profit23.63M12.59M-1.84M-6.06M-3.63M
EBITDA7.05M-3.03M-11.29M-14.93M-10.34M
Net Income792.13K-11.31M-17.35M-13.95M-9.58M
Balance Sheet
Total Assets98.78M95.91M78.44M80.92M21.27M
Cash, Cash Equivalents and Short-Term Investments15.58M14.20M7.58M7.15M12.35M
Total Debt12.61M13.09M13.41M9.16M1.42M
Total Liabilities47.20M47.45M43.89M32.07M4.25M
Stockholders Equity51.58M48.46M34.55M48.45M16.66M
Cash Flow
Free Cash Flow3.35M-1.63M-548.13K-12.94M-9.00M
Operating Cash Flow5.19M-1.45M-236.32K-12.54M-8.68M
Investing Cash Flow-2.80M-3.23M-290.79K-43.36M230.68K
Financing Cash Flow-831.97K12.42M1.86M50.72M16.39M

MedAdvisor Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.06
Price Trends
50DMA
0.07
Negative
100DMA
0.09
Negative
200DMA
0.16
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
37.15
Neutral
STOCH
1.20
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MDR, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.16, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 37.15 is Neutral, neither overbought nor oversold. The STOCH value of 1.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:MDR.

MedAdvisor Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
AU$40.64M110.00-8.34%-5.27%50.29%
55
Neutral
AU$72.13M-457.46%21.93%10.34%
53
Neutral
AU$147.72M-5.63%-11.96%7.50%
52
Neutral
AU$75.55M-11.80%14.56%13.36%
51
Neutral
$7.39B0.36-62.86%2.37%15.48%-2.68%
50
Neutral
AU$25.68M-74.80%-9.16%89.23%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:MDR
MedAdvisor Limited
0.06
-0.39
-86.67%
AU:BMT
Beamtree Holdings Ltd
0.26
-0.02
-7.14%
AU:ALC
Alcidion Group Limited
0.11
0.04
57.14%
AU:EMD
Emyria Ltd
0.05
0.01
25.00%
AU:PCK
PainChek Ltd
0.04
0.00
0.00%

MedAdvisor Limited Corporate Events

MedAdvisor Limited Shares Investor Insights Amidst Market Uncertainties
Jul 31, 2025

MedAdvisor Limited’s recent investor presentation outlines general information about the company’s current standing and future prospects. The presentation emphasizes that it is not a formal offer or financial advice, highlighting the inherent risks and uncertainties in forward-looking statements. Stakeholders are advised to conduct independent assessments of MedAdvisor’s market position and potential future performance, as the presentation is not a substitute for detailed investment analysis.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Reports FY25 Revenue Decline Amid Strategic Restructuring
Jul 31, 2025

MedAdvisor Limited reported a decline in revenue and gross profit for the fourth quarter and full fiscal year 2025, attributed to budgetary pressures and delayed health program rollouts. Despite these challenges, the company completed a successful capital raise and accelerated its Transformation 360 initiative to improve future performance. The sale of its ANZ business to Jonas Software for $35 million has left MedAdvisor debt-free, and the company is considering strategic options, including a potential sale of its US business. The deferred revenue and a strong pipeline of US$125 million provide confidence for a solid first half of fiscal year 2026.

The most recent analyst rating on (AU:MDR) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Announces 4Q FY25 Results Webinar
Jul 30, 2025

MedAdvisor Limited has announced a webinar for the presentation of its 4Q FY25 results, to be delivered by CEO Rick Ratliff and incoming CFO Sean Slattery. This event, scheduled for July 31, 2025, will provide insights into the company’s performance and future outlook, potentially impacting its operations and stakeholder interests.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Limited Announces Virtual Extraordinary General Meeting
Jul 22, 2025

MedAdvisor Limited has announced a virtual Extraordinary General Meeting (EGM) scheduled for August 21, 2025. This meeting aims to address key business matters and engage shareholders through an online platform, reflecting the company’s commitment to leveraging digital solutions for stakeholder engagement.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Issues Unquoted Securities to Boost Employee Incentives
Jul 18, 2025

MedAdvisor Limited has announced the issuance of 19,826,251 unquoted securities under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize employees, potentially impacting its operational dynamics and aligning staff interests with company growth objectives.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Appoints New CFO Amid Strategic Review
Jul 17, 2025

MedAdvisor Limited has appointed Mr. Sean Slattery as the new Chief Financial Officer and Company Secretary, effective July 21, 2025. Mr. Slattery, who previously served as CFO at Rhinomed Limited, will play a crucial role in MedAdvisor’s strategic review, which includes the potential sale of its U.S. business. His appointment comes at a pivotal time as the company seeks to unlock shareholder value. The transition will be facilitated by working alongside the current CFO, Ms. Ancila Desai, ensuring a smooth handover.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Limited Announces Quotation of New Securities on ASX
Jul 10, 2025

MedAdvisor Limited announced the quotation of 469,046 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from July 14, 2025. This move reflects the company’s strategic efforts to enhance its financial positioning and potentially expand its market presence, offering implications for stakeholders regarding increased liquidity and investment opportunities.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.11 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

Jencay Capital Increases Stake in MedAdvisor Limited
Jul 8, 2025

Jencay Capital Pty Limited, a substantial holder in MedAdvisor Limited, has increased its voting power from 7.24% to 8.39% by purchasing an additional 9,142,870 ordinary shares. This change in shareholding indicates a growing interest and confidence in MedAdvisor’s operations, potentially impacting the company’s market positioning and signaling positive implications for stakeholders.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Limited Announces Investor Webinar on Strategic Developments
Jul 7, 2025

MedAdvisor Limited has announced an investor webinar to discuss the sale of its ANZ operations and provide updates on its strategic options review process. This move could significantly impact the company’s operations and market positioning, as it seeks to streamline its focus and potentially enhance shareholder value.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Completes Sale of ANZ Operations to Jonas Software
Jul 7, 2025

MedAdvisor Limited has completed the sale of its ANZ business operations and related intellectual property to Jonas Software for an estimated total transaction value of $42.35 million. This strategic move allows MedAdvisor to focus on its US operations while maintaining its ASX listing. The transaction involves a $35 million headline price, with an additional earn-out potential of $7.35 million based on future performance. The sale will enable MedAdvisor to discharge its financial obligations and marks a significant shift in its operational focus. Additionally, the company’s CFO, Mrs. Ancila Desai, will be stepping down following the transaction.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Sells ANZ Business to Jonas Software for Strategic Refocus
Jul 2, 2025

MedAdvisor Limited has entered into a binding agreement to sell its ANZ business division and related intellectual property to Jonas Software AUS Pty Ltd for a headline price of $35 million, with potential additional earnings based on future performance. This strategic move will allow MedAdvisor to focus on its US operations, while the sale proceeds will be used to settle existing debts and potentially return capital to shareholders, pending post-completion adjustments.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Announces Change in Substantial Holder’s Interests
Jun 5, 2025

MedAdvisor Limited has announced a change in the interests of its substantial holder, Guild Group Holdings Limited, which now holds 94,905,130 fully paid ordinary shares. This change reflects a reduction in Guild Group Holdings Limited’s voting power due to non-participation in a capital raising offer, while they participated in an entitlement offer, impacting their voting power from 18% to 15.19%.

The most recent analyst rating on (AU:MDR) stock is a Buy with a A$0.53 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

Mercer Investments Sells Stake in MedAdvisor
May 20, 2025

MedAdvisor Limited, a company in the healthcare technology sector, is known for its digital medication management solutions. Recently, Mercer Investments (Australia) Limited, acting as the responsible entity of the Mercer Australian Small Companies Fund, has ceased to be a substantial holder in MedAdvisor Limited as of May 16, 2025. This change involved the sale of 2,565,351 shares, potentially impacting MedAdvisor’s shareholder structure and market perception.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Limited Announces Quotation of New Securities on ASX
May 19, 2025

MedAdvisor Limited has announced the quotation of 389,420 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 20, 2025. This move is part of the company’s strategy to enhance its financial flexibility and potentially strengthen its market position, which could have implications for its stakeholders and operations.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Announces Change in Substantial Holder Interests
May 16, 2025

MedAdvisor Limited has announced a change in the interests of its substantial holder, EBOS Group Limited, which is a key player in the healthcare and pharmaceutical distribution industry. The announcement indicates a dilution in EBOS’s voting power from 9.81% to 8.65% due to the issuance of new shares by MedAdvisor, including a recent placement and share purchase plan. This change reflects a strategic adjustment in the company’s shareholder structure, potentially impacting its governance dynamics and stakeholder interests.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Limited Announces Quotation of New Securities
May 14, 2025

MedAdvisor Limited has announced the quotation of 26,680,000 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility, potentially impacting its market positioning positively.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Completes Oversubscribed Share Purchase Plan
May 14, 2025

MedAdvisor Limited has successfully completed its Share Purchase Plan (SPP), raising A$2.668 million, exceeding its initial target of A$2 million. This funding will support the company’s strategic initiatives and provide additional working capital, with the new shares set to begin trading on 16 May 2025. The company also plans to hold an Extraordinary General Meeting to approve shares committed by directors in a previous placement.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Enters Potential Sale Agreement for ANZ Division
May 9, 2025

MedAdvisor Limited has entered into a non-binding Letter of Intent with a subsidiary of a major multinational software company to sell its ANZ business division and associated intellectual property. The potential transaction, valued at $35 million with an additional earn-out component, could significantly impact MedAdvisor’s operations and market positioning by aligning with a company that has a substantial market capitalization and revenue.

MedAdvisor Initiates Trading Halt Amid Strategic Update
May 7, 2025

MedAdvisor Limited has requested a trading halt on its securities as it prepares to release an announcement regarding a strategic update. This halt is related to a non-binding proposal to acquire its ANZ business division, indicating potential significant changes in its operational focus and market strategy.

MedAdvisor Receives Acquisition Proposal for ANZ Division
May 6, 2025

MedAdvisor Limited has received a non-binding Letter of Intent from a multinational software company to acquire its ANZ business division, which the directors believe offers a materially higher value than the current share price. This proposal aligns with MedAdvisor’s strategic review process aimed at bridging the valuation gap of its ANZ and US business units. The ANZ division recently achieved record revenue, and the potential acquirer plans to continue investing in the business, benefiting pharmacies across Australia. The transaction, subject to due diligence, is expected to be finalized within 5 to 7 weeks.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 02, 2025